Lycia Therapeutics (LYCA) 10% Owner L.P. Buys $1.1M of Stock
Key Points
- Venrock Healthcare Capital Partners III, L.P. purchased 39,796 shares of Lycia Therapeutics at a price of $26.62 each, totaling approximately $1.06 million.
- After this transaction, Venrock holds a total of 6,825,233 shares, which is an increase of about 0.59% in their ownership stake.
- The stock recently traded around $26.11, which is about 28.4% below its 52-week high of $36.49.
Get Lycia Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $LYCA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Lycia Therapeutics, Inc. alert may contain errors. Disclosures
On October 27, 2026, Venrock Healthcare Capital Partners III, L.P. bought 39,796 shares of Lycia Therapeutics, Inc. at a price of $26.62 each, totaling approximately $1,059,397. This trade was reported in a Form 4 filing with the SEC.
Venrock's purchase increased its total holdings to 6,825,233 shares, reflecting a 0.59% increase in their stake in the company. As a 10% owner, Venrock's investment shows confidence in Lycia's potential in the biotechnology sector.
LYCA
Lycia Therapeutics, Inc.
Venrock Healthcare Capital Partners III, L.P. vs. the S&P 500
Hypothetical returns from Venrock Healthcare Capital Partners III, L.P.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Lycia Therapeutics
There are no reported changes from other institutional investors in Lycia Therapeutics at this time.
Lycia Therapeutics, Inc. Stock Down 9.5%
The stock recently traded around $26.11, which is about 28.4% below its 52-week high of $36.49. This decline suggests that the shares may be undervalued compared to their recent peak, especially as they are also trading below their 50-day and 200-day moving averages, currently at $29.43. The stock's performance in the coming weeks may be closely watched by investors as it navigates this lower trading range.
Recent Earnings
Lycia Therapeutics reported trailing twelve-month revenue of approximately $4.44 million, but it has not yet turned a profit, with an EPS of -$1.04. The next earnings date has not been announced, which leaves investors looking for updates on their financial progress.
About Lycia Therapeutics
Lycia Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies aimed at degrading harmful extracellular proteins. Their work targets treatments for autoimmune and inflammatory diseases through their innovative LYTAC platform.
Bottom Line
Investors will be watching for future earnings announcements and any further insider trading activity. As of now, Venrock's recent purchase indicates continued interest in Lycia's potential despite the current stock price being below its recent highs.
Related Filing Alerts
Source: Venrock Healthcare Capital Partners III, L.P.'s Form 4 filing on $LYCA (Oct 27, 2026). Written by software, not financial advice. How we make alerts